| CAS | 16941-32-5 |
| Sequence | H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH |
| Sequence Single | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT |
| Molecular Formula | C153H225N43O49S |
| Molecular Weight | 3482.8 |
| Synonyms | Glucagon, human |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Diabetes|Veterinary Medicine |
| Description | Glucagon (1-29) (human, rat, porcine) also called Glucagon, human, is a 29 amino acid containing peptide hormone processed from proglucagon. As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo in both animals and humans. Not surprisingly, glucagon and glucagon receptor have been pursued extensively as potential targets for the therapeutic treatment of diabetes. As Aβ peptides and IAPP, glucacon tends to form gel-like fibrillar aggregates. These fibrils were found to be toxic through the activation of apoptotic signaling pathways. Hence the aggregation behavior of glucagon has been studied extensively. Glucagon stimulates gluconeogenesis. Glucagon activates HNF4α and increases HNF4α phosphorylation. |
| References | 1. Spectroscopic evidence for the existence of an obligate pre-fibrillar oligomer during glucagon fibrillation. A.S.Dutta, Drugs Future, 13, 43 (1988) 2. N- and C-terminal hydrophobic patches are involved in fibrillation of glucagon. P.A.Christensen et al., FEBS Lett., 582, 1341 (2008) 3. Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J.S.Pedersen et al., Biochemistry, 45, 14503 (2006) 4. Glucagon and regulation of glucose metabolism. S.Onoue et al., J. Chromatogr. A, 1109, 167 (2006) |